Molina Healthcare, Inc.

Molina Healthcare, Inc. (MOH) Market Cap

Molina Healthcare, Inc. has a market capitalization of $7.76B.

Financials based on reported quarter end 2025-12-31

Price: $148.97

β–² 0.10 (0.07%)

Market Cap: 7.76B

NYSE Β· time unavailable

CEO: Joseph Michael Zubretsky

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2003-07-02

Website: https://www.molinahealthcare.com

Molina Healthcare, Inc. (MOH) - Company Information

Market Cap: 7.76B Β· Sector: Healthcare

Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. As of December 31, 2021, the company served the company served approximately 5.2 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 18 states. The company was founded in 1980 and is headquartered in Long Beach, California.

Analyst Sentiment

53%
Hold

Based on 19 ratings

Analyst 1Y Forecast: $193.59

Average target (based on 3 sources)

Consensus Price Target

Low

$124

Median

$158

High

$310

Average

$176

Potential Upside: 17.9%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ Molina Healthcare, Inc. (MOH) β€” Investment Overview

🧩 Business Model Overview

Molina Healthcare, Inc. is a managed care company focused on providing government-sponsored health insurance programs. The company primarily serves individuals and families who qualify for Medicaid, Medicare, and state-based Marketplace programs, emphasizing access to quality healthcare for underserved populations. Molina Healthcare operates through a network of health plans and subsidiaries across multiple states, administering healthcare benefits under contracts with state and federal governments. Its service delivery includes care coordination, medical management, and member engagement, with the aim of enhancing outcomes and controlling costs for large, complex populations.

πŸ’° Revenue Model & Ecosystem

Molina Healthcare derives the majority of its revenues from capitated payments and premiums received from government agencies. These risk-adjusted payments are based on the number and mix of enrolled members rather than fee-for-service transactions, aligning incentives for cost-effective care management. The company also participates in certain value-based payment arrangements, performance incentives, and administrative service contracts. Its ecosystem consists of healthcare providers, hospitals, pharmacies, and government partners, reinforced by investments in digital health tools, care management technologies, and member services aimed at improving engagement and satisfaction.

🧠 Competitive Advantages

  • Brand strength: Molina’s longstanding focus on serving Medicaid and dual-eligible populations has built strong relationships with government stakeholders and a positive reputation as a partner for public sector health programs.
  • Switching costs: Members enrolled in government programs often face high switching barriers due to plan enrollment cycles, network familiarity, and continuity of care relationships, contributing to low member churn rates.
  • Ecosystem stickiness: Molina’s tightly integrated provider networks, care management platforms, and compliance infrastructure foster a high degree of dependency with state agencies and provider partners alike.
  • Scale + supply chain leverage: The company’s national footprint and significant managed membership base allows for favorable contract negotiation with healthcare providers, as well as economies of scale in administrative operations and technology deployment.

πŸš€ Growth Drivers Ahead

Molina Healthcare’s long-term growth will likely be driven by expanded Medicaid eligibility, new Medicaid contract awards, and continued penetration in Medicare Advantage and Marketplace segments. The company is positioned to benefit from ongoing health policy trends favoring managed care models, as well as potential expansion of government healthcare programs at the state and federal levels. In addition, selective acquisitions, geographic expansion, and investments in population health analytics provide opportunities for further market share gains and service differentiation. Molina’s ability to partner with states facing budgetary and regulatory pressures may offer a competitive edge in capturing new contract opportunities and innovating in supplemental services.

⚠ Risk Factors to Monitor

Key risks to the Molina Healthcare investment thesis include policy or regulatory changes affecting Medicaid and Medicare funding levels, reimbursement rates, or eligibility criteria. The managed care landscape remains highly competitive, with both national insurers and regional players vying for government contracts. Margin pressures may arise from medical cost inflation, adverse member mix, or unanticipated utilization spikes. Molina is also exposed to disruption risk from emerging healthcare delivery models, regulatory scrutiny, and the need for continual investment in compliance and technology to keep pace with evolving standards.

πŸ“Š Valuation Perspective

Molina Healthcare is typically valued by the market in the context of its managed care peer group. The company’s historical focus on Medicaid and disciplined operating model has, at times, resulted in a valuation premium versus regional peers, especially in periods of strong contract wins or operating performance. However, valuation can be sensitive to perceived risks around contract renewals, reimbursement changes, and execution in new markets. The market often distinguishes Molina for its pure-play focus and ability to generate consistent margins despite operating in complex segments of healthcare.

πŸ” Investment Takeaway

Molina Healthcare offers focused exposure to U.S. government healthcare programs, with a demonstrated track record in navigating regulatory complexities and delivering consistent member outcomes. The bull case rests on the company’s ability to capitalize on expansion in Medicaid and government health spending, supported by operational scale and strong provider relationships. Bearish scenarios emphasize heightened policy risks, execution challenges in new markets, and persistent competitive pressures. Ultimately, Molina represents a healthcare growth story anchored by expertise in public sector partnerships, but one requiring close monitoring of the evolving regulatory and competitive landscape.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Q4 results were weak, with an adjusted loss and elevated MCRs across Medicare and Marketplace, compounded by retroactive Medicaid actions in California. FY2025 underperformed initial guidance as trend and acuity rose, particularly in Marketplace. Management reset 2026 guidance to at least $5 EPS and ~0.8% pretax margin, framing 2026 as a Medicaid margin trough while strategically shrinking Marketplace, transitioning Medicare to integrated dual products, and exiting MAPD by 2027. Despite near-term headwinds, strong RFP wins (notably Florida CMS), an active pipeline, and embedded earnings support a more constructive longer-term outlook contingent on rate restoration and trend moderation.

Growth

  • FY2025 premium revenue up 11% YoY to $43.1B
  • Won sole Florida Children’s Medical Services (CMS) Medicaid contract (~$6B annual run-rate), expected go-live late 2026
  • Renewed Wisconsin MyChoice LTSS (Regions 2 & 7); previously won Georgia Medicaid and Texas STAR/CHIP (now expected to start in 2027)
  • RFP win rates: 90% on renewals ($14B retained) and 80% on new awards ($20B new); ~$50B active RFP pipeline
  • Active, actionable M&A pipeline; plan to deploy capital to accretive deals
  • Embedded earnings from awarded-not-yet-live contracts now exceed $11/share

Business Development

  • Awarded sole Florida CMS Medicaid contract (~$6B annual premium; late-2026 start)
  • Renewed Wisconsin MyChoice LTSS contract (Regions 2 & 7)
  • Georgia Medicaid and Texas STAR/CHIP previously awarded; implementations now expected in 2027 (excluded from 2026 guidance)
  • RFP pipeline of ~$50B with strong historic win rates (90% renewals, 80% new)
  • Opportunistic M&A pursued amid challenging environment for smaller plans

Financials

  • Q4 premium revenue $10.7B; adjusted EPS -$2.75
  • Q4 MCRs: Medicaid 93.5% (impacted by CA retro items); Medicare 97.5%; Marketplace 99%
  • Adjusting for CA retro items (risk corridor and retro rate cuts totaling 160 bps), Q4 Medicaid MCR 92.3% and pretax margin ~2%
  • FY2025 adjusted EPS $11.03; pretax margin 1.6%
  • FY2025 Medicaid: MCR 91.8%, pretax margin 2.8%; rates +6% vs trend +7.5% (incl. ~250 bps acuity from redeterminations)
  • Adjusted G&A ratio: 6.9% in Q4; 6.5% for FY2025
  • 2026 guidance: premium revenue ~ $42B; pretax margin ~0.8%; adjusted EPS at least $5
  • Drivers of EPS downgrade vs prior ~$14 outlook: ~$6.50 from higher Medicaid MCR (incl. continued CA retro items ~40 bps, Florida CMS start-up ~30 bps, and rates matchingβ€”not exceedingβ€”trend), ~$1 from Medicare (MAPD underperformance), and ~$1.50 from higher tax/interest and lower volume net of G&A savings
  • 2026 segment premium outlook: Medicaid +$1.1B (Florida CMS, modest rates; offset Virginia loss and slight market contraction); Medicare +$300M (mix shift to integrated products); Marketplace -$2.3B (intentional exposure reduction)

Capital & Funding

  • RBC ratios ~305% in aggregate (>50% above state minimums)
  • Issued $850M senior notes due 2031; used to repay term loans and for general corporate purposes
  • Leverage: ~3.7x trailing 12-month EBITDA; debt-to-capital ~49%
  • Bank covenants amended to align with current guidance
  • Harvested ~$337M subsidiary dividends in Q4; parent cash ~$223M at year-end
  • 2025 operating cash flow outflow ~$535M (Medicaid risk corridor settlements, tax timing, weaker 2H performance)
  • Days in claims payable 47; management expresses confidence in reserves

Operations & Strategy

  • Reducing Marketplace exposure by ~50% in 2026 to stabilize margins; average pricing up ~30% (range 15%–45%); renewal mix ~70%
  • Medicare portfolio shifting to integrated dual-eligible products; expect lower first-year margins; exiting traditional MAPD in 2027
  • Medicaid remains core focus; manage through rate/trend imbalance with expectation of low single-digit margins in 2026 (cycle trough)
  • Ongoing cost discipline and fixed-cost leverage; FY2025 adjusted G&A 6.5%
  • Florida CMS start-up expected to pressure margins in Q4 2026 before normalizing
  • Every 100 bps improvement in Medicaid MCR is worth nearly $5/share in EPS

Market & Outlook

  • 2026 assumptions: Medicaid rates ~4% vs medical cost trend ~5%; Medicare transitioning to integrated products; Marketplace premium reduced by ~50%
  • Management views 2026 as trough for Medicaid margins; sector underfunding estimated at 300–400 bps; expects actuarial soundness and off-/late-cycle rate actions to restore margins over time
  • Potential upside to 2026 guidance from moderating Medicaid trend, favorable rate actions, and better-than-assumed Medicare/Marketplace performance
  • 2026 membership outlook: Medicaid YE ~4.6M (flat YoY, includes Florida CMS from Oct-2026); Medicare ~230k; Marketplace YE ~220k (Q1 ~280k)
  • Investor Day planned for Friday, May 8 to detail long-term goals and strategy

Risks Or Headwinds

  • Medicaid rate/trend imbalance and underfunding (~300–400 bps); exposure to retroactive state actions (e.g., California risk corridor and rate reductions continuing into 2026, ~40 bps pressure)
  • Elevated utilization across lines (LTSS, behavioral health, high-cost drugs, professional/outpatient visits)
  • Marketplace volatility from expiring enhanced subsidies and program integrity initiatives; uncertain retention through grace periods
  • Start-up margin pressure from Florida CMS launch and slower-than-expected MAPD recovery; MAPD exit planned for 2027
  • Delayed starts for Georgia Medicaid and Texas STAR/CHIP to 2027
  • Higher effective tax rate and interest expense; leverage at ~3.7x with amended covenants
  • Ongoing Medicaid eligibility reviews could pressure membership mix and acuity

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the MOH Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Molina Healthcare reported revenue of $11.38 billion for Q4 2025, with a net income of -$160 million and an EPS of -3.15, reflecting a challenging period with negative net margin and high free cash flow consumption. The operating cash flow was intensely negative at -$298 million, and while capital expenditure remained low, the free cash flow was still negative at -$297 million due to deficits in operational performance. In terms of growth, MOH has seen fluctuations which suggest instability, possibly due to increased costs or revenue pressure. Profitability is under strain, with negative net income and operating cash flow suggesting inefficiencies or high unanticipated expenses. Cash reserves appear strong at $4.25 billion, with net debt effectively zero, portraying a solid balance sheet, although cash outflows are concerning. With no dividends or buybacks, shareholder value relies on potential capital gains, though market sentiment is cautious. Analysts show a moderate target consensus of $181, indicating wary optimism. The need for improved operational efficiency and cost management is evident to restore profitability."

Revenue Growth

Fair

Growth is present in absolute terms, but stability is questionable as revenue fails to translate into positive earnings.

Profitability

Neutral

Negative net income and EPS point to profitability challenges, with pressures likely from cost structure and pricing.

Cash Flow Quality

Neutral

Negative operating cash flow and FCF highlight liquidity issues despite strong cash reserves; unsustainable without operational improvements.

Leverage & Balance Sheet

Neutral

Strong cash position and lack of net debt indicate financial resilience, though operational losses could strain this over time.

Shareholder Returns

Neutral

Absence of dividends and buybacks limits direct shareholder returns; future appreciation hinges on profit recovery.

Analyst Sentiment & Valuation

Fair

Mixed analyst outlook with a consensus target of $181 reflecting cautious optimism; valuation dependent on reversing losses.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
πŸ“

SEC Filings (MOH)

Β© 2026 Stock Market Info β€” Molina Healthcare, Inc. (MOH) Financial Profile